We understand the unique metabolic challenges GLP-1 patients face and have optimized our NAD+ protocol to address these specific needs." Get Thin MD Clinical Team Why Choose Get Thin MD for Your NAD+ Therapy
People in the field have questioned if there was anything GLP-1 drugs couldnt do
One fatal, serious adverse event, small cell lung carcinoma with dissemination, occurred in the 6 mg group but was deemed unrelated to trial participation
Other Ingredients: Microcrystalline Cellulose, Vegetable Capsule, Magnesium Stearate, Silicon Dioxide
Coverage depends on the independent BCBS company, the member's exact plan and benefit year, employer choices, the prescribed product and FDA-labeled indication, and any prior-approval rules